Knight Therapeutics Acquires Exclusive Marketing Rights to Nerlynx in Canada

Knight Therapeutics Acquires Exclusive Marketing Rights to Nerlynx in Canada
Breast cancer treatment Nerlynx (neratinib) will be exclusively commercialized in Canada by Knight Therapeutics, under an agreement with the therapy's developer, Puma Biotechnology. Nerlynx is currently being reviewed by Health Canada as a way to reduce the risk of recurrence among breast cancer patients who underwent surgery and received trastuzumab-based therapy. According to the terms of the exclusive licensing agreement, Knight will be responsible for all commercial activities and future regulatory submissions of Nerlynx in Canada. "We are excited to partner with Puma to offer a new treatment option to Canadian breast cancer patients," Jonathan Ross Goodman, CEO of Knight, said in a press release. "While adjuvant trastuzumab-based therapy has been shown to reduce the risk of recurrence in early stage HER2-positive breast cancer, up to 25% of patients treated with adjuvant trastuzumab will have a recurrence. Nerlynx has been shown to significantly reduce the risk of recurrence in those patients who were previously treated with trastuzumab," he added. Nerlynx works by blocking the action of several proteins that promote cell growth, including epidermal growth factor receptors (EGFRs) and human epidermal growth factor receptor 2 (HER2). The treatment is already approved in the U.S. and Europe as an extended adjuvant treatment for early-stage, HER2-positive breast cancer patients who received prior Herceptin (trastuzumab) or a trastuzumab-based therapy as part of their adjuvant treatment. An adjuvant treatment is one given after the primary treatment – usually surgery – to lower the risk that the cancer will come back. The approvals were supported by data from the ExteNET Phase 3 trial (NCT00878709), where Nerlynx significantly delayed
Subscribe or to access all post and page content.